Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Precision medicine and the antiphospholipid syndrome: what is the future?

Rodriguez-Pintó I, Espinosa G, Cervera R.

Clin Rheumatol. 2020 Feb 15. doi: 10.1007/s10067-020-04987-8. [Epub ahead of print] No abstract available.

PMID:
32060811
2.

Plasma exchange in catastrophic antiphospholipid syndrome.

Rodríguez-Pintó I, Lozano M, Cid J, Espinosa G, Cervera R.

Presse Med. 2019 Nov;48(11 Pt 2):347-353. doi: 10.1016/j.lpm.2019.10.003. Epub 2019 Nov 4. Review.

PMID:
31694791
3.

The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort.

Radin M, Sciascia S, Erkan D, Pengo V, Tektonidou MG, Ugarte A, Meroni P, Ji L, Belmont HM, Cohen H, Ramires de Jesús G, Branch DW, Fortin PR, Andreoli L, Petri M, Rodriguez E, Rodriguez-Pinto I, Knight JS, Atsumi T, Willis R, Gonzalez E, Lopez-Pedrera R, Rossi Gandara AP, Borges Gualhardo Vendramini M, Banzato A, Sevim E, Barbhaiya M, Efthymiou M, Mackie I, Bertolaccini ML, Andrade D; APS ACTION.

Semin Arthritis Rheum. 2019 Dec;49(3):464-468. doi: 10.1016/j.semarthrit.2019.04.009. Epub 2019 May 2.

PMID:
31153708
4.

The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis.

Sciascia S, Willis R, Pengo V, Krilis S, Andrade D, Tektonidou MG, Ugarte A, Chighizola C, Branch DW, Levy RA, Nalli C, Fortin PR, Petri M, Rodriguez E, Rodriguez-Pinto I, Atsumi T, Nascimento I, Rosa R, Banzato A, Erkan D, Cohen H, Efthymiou M, Mackie I, Bertolaccini ML; APS ACTION.

Thromb Res. 2019 Mar;175:32-36. doi: 10.1016/j.thromres.2019.01.010. Epub 2019 Jan 18.

PMID:
30685523
5.

The H1 haplotype of the endothelial protein C receptor protects against arterial thrombosis in patients with antiphospholipid syndrome.

Plasín-Rodríguez MA, Rodríguez-Pintó I, Patricio P, Monteagudo J, Cervera R, Reverter JC, Espinosa G, Tàssies D.

Thromb Res. 2018 Sep;169:128-134. doi: 10.1016/j.thromres.2018.07.006. Epub 2018 Jul 4.

PMID:
30048851
6.

McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome.

Legault K, Schunemann H, Hillis C, Yeung C, Akl EA, Carrier M, Cervera R, Crowther M, Dentali F, Erkan D, Espinosa G, Khamashta M, Meerpohl JJ, Moffat K, O'Brien S, Pengo V, Rand JH, Rodriguez Pinto I, Thom L, Iorio A.

J Thromb Haemost. 2018 Jun 7. doi: 10.1111/jth.14192. [Epub ahead of print]

PMID:
29978552
7.

The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review.

Cervera R, Rodríguez-Pintó I, Espinosa G.

J Autoimmun. 2018 Aug;92:1-11. doi: 10.1016/j.jaut.2018.05.007. Epub 2018 May 18. Review.

PMID:
29779928
8.

The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients.

Rodríguez-Pintó I, Espinosa G, Erkan D, Shoenfeld Y, Cervera R; CAPS Registry Project Group .

Rheumatology (Oxford). 2018 Jul 1;57(7):1264-1270. doi: 10.1093/rheumatology/key082.

PMID:
29660074
9.

All that glitters is not lupus.

López-Mato P, Zamora-Martínez C, Carbajal S, Estevez M, Rodriguez-Pinto I, Cervera R, Prieto-González S, Espinosa G.

Lupus. 2017 Jan 1:961203317742713. doi: 10.1177/0961203317742713. [Epub ahead of print] No abstract available.

PMID:
29153011
10.

Catastrophic antiphospholipid syndrome: an update.

Espinosa G, Rodríguez-Pintó I, Cervera R.

Panminerva Med. 2017 Sep;59(3):254-268. doi: 10.23736/S0031-0808.17.03324-9. Epub 2017 May 8. Review.

PMID:
28488841
11.

Peripheral nervous system involvement in systemic lupus erythematosus: Prevalence, clinical and immunological characteristics, treatment and outcome of a large cohort from a single centre.

Toledano P, Orueta R, Rodríguez-Pintó I, Valls-Solé J, Cervera R, Espinosa G.

Autoimmun Rev. 2017 Jul;16(7):750-755. doi: 10.1016/j.autrev.2017.05.011. Epub 2017 May 5.

PMID:
28483540
12.

Local Delivery of the Toll-Like Receptor 9 Ligand CpG Downregulates Host Immune and Inflammatory Responses, Ameliorating Established Leishmania (Viannia) panamensis Chronic Infection.

Ehrlich AK, Fernández OL, Rodriguez-Pinto D, Castilho TM, Corral Caridad MJ, Goldsmith-Pestana K, Saravia NG, McMahon-Pratt D.

Infect Immun. 2017 Feb 23;85(3). pii: e00981-16. doi: 10.1128/IAI.00981-16. Print 2017 Mar.

13.

Catastrophic antiphospholipid syndrome: The current management approach.

Rodriguez-Pintó I, Espinosa G, Cervera R.

Best Pract Res Clin Rheumatol. 2016 Apr;30(2):239-249. doi: 10.1016/j.berh.2016.07.004. Epub 2016 Sep 12. Review.

PMID:
27886797
14.

Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry.

Rodríguez-Pintó I, Moitinho M, Santacreu I, Shoenfeld Y, Erkan D, Espinosa G, Cervera R; CAPS Registry Project Group (European Forum on Antiphospholipid Antibodies).

Autoimmun Rev. 2016 Dec;15(12):1120-1124. doi: 10.1016/j.autrev.2016.09.010. Epub 2016 Sep 15. Review.

PMID:
27639837
15.

Maximum swimming speeds of sailfish and three other large marine predatory fish species based on muscle contraction time and stride length: a myth revisited.

Svendsen MB, Domenici P, Marras S, Krause J, Boswell KM, Rodriguez-Pinto I, Wilson AD, Kurvers RH, Viblanc PE, Finger JS, Steffensen JF.

Biol Open. 2016 Oct 15;5(10):1415-1419. doi: 10.1242/bio.019919.

16.

Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study.

Amengual O, Forastiero R, Sugiura-Ogasawara M, Otomo K, Oku K, Favas C, Delgado Alves J, Žigon P, Ambrožič A, Tomšič M, Ruiz-Arruza I, Ruiz-Irastorza G, Bertolaccini ML, Norman GL, Shums Z, Arai J, Murashima A, Tebo AE, Gerosa M, Meroni PL, Rodriguez-Pintó I, Cervera R, Swadzba J, Musial J, Atsumi T.

Lupus. 2017 Mar;26(3):266-276. doi: 10.1177/0961203316660203. Epub 2016 Aug 20.

PMID:
27510605
17.

The problems and pitfalls in systemic lupus erythematosus drug discovery.

Rodríguez-Pintó I, Espinosa G, Cervera R.

Expert Opin Drug Discov. 2016 Jun;11(6):525-7. doi: 10.1080/17460441.2016.1181056. Epub 2016 May 5. No abstract available.

PMID:
27100941
18.

A visual horizon affects steering responses during flight in fruit flies.

Caballero J, Mazo C, Rodriguez-Pinto I, Theobald JC.

J Exp Biol. 2015 Sep;218(Pt 18):2942-50. doi: 10.1242/jeb.119313. Epub 2015 Jul 31.

19.

Development and validation of a risk calculator to differentiate flares from infections in systemic lupus erythematosus patients with fever.

Beça S, Rodríguez-Pintó I, Alba MA, Cervera R, Espinosa G.

Autoimmun Rev. 2015 Jul;14(7):586-93. doi: 10.1016/j.autrev.2015.02.005. Epub 2015 Feb 20. Review.

PMID:
25703012
20.

Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome.

Rodríguez-Pintó I, Cervera R, Espinosa G.

Ther Adv Musculoskelet Dis. 2015 Feb;7(1):26-30. doi: 10.1177/1759720X14554793. Review.

21.

Catastrophic APS in the context of other thrombotic microangiopathies.

Rodríguez-Pintó I, Espinosa G, Cervera R.

Curr Rheumatol Rep. 2015 Jan;17(1):482. doi: 10.1007/s11926-014-0482-z. Review.

PMID:
25604575
22.

Catastrophic antiphospholipid syndrome: an orchestra with several musicians.

Rodríguez-Pintó I, Soriano A, Espinosa G, Shoenfeld Y, Cervera R.

Isr Med Assoc J. 2014 Sep;16(9):585-6. No abstract available.

23.

Catastrophic antiphospholipid syndrome: task force report summary.

Cervera R, Rodríguez-Pintó I; G Espinosa on behalf of the Task Force on Catastrophic Antiphospholipid Syndrome.

Lupus. 2014 Oct;23(12):1283-5. doi: 10.1177/0961203314540764.

PMID:
25228727
24.

14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome.

Cervera R, Rodríguez-Pintó I, Colafrancesco S, Conti F, Valesini G, Rosário C, Agmon-Levin N, Shoenfeld Y, Ferrão C, Faria R, Vasconcelos C, Signorelli F, Espinosa G.

Autoimmun Rev. 2014 Jul;13(7):699-707. doi: 10.1016/j.autrev.2014.03.002. Epub 2014 Mar 20.

PMID:
24657970
25.

CD4 T cell activation by B cells in human Leishmania (Viannia) infection.

Rodriguez-Pinto D, Saravia NG, McMahon-Pratt D.

BMC Infect Dis. 2014 Feb 25;14:108. doi: 10.1186/1471-2334-14-108.

26.

Fibromyalgia and cytokines.

Rodriguez-Pintó I, Agmon-Levin N, Howard A, Shoenfeld Y.

Immunol Lett. 2014 Oct;161(2):200-3. doi: 10.1016/j.imlet.2014.01.009. Epub 2014 Jan 23. Review.

PMID:
24462815
27.

Treatment with angiotensin II receptor blockers is associated with prolonged relapse-free survival, lower relapse rate, and corticosteroid-sparing effect in patients with giant cell arteritis.

Alba MA, García-Martínez A, Prieto-González S, Espígol-Frigolé G, Butjosa M, Tavera-Bahillo I, Rodríguez-Pintó I, Hernández-Rodríguez J, Cid MC.

Semin Arthritis Rheum. 2014 Jun;43(6):772-7. doi: 10.1016/j.semarthrit.2013.10.009. Epub 2013 Oct 30.

PMID:
24315461
28.

Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the "CAPS Registry".

Berman H, Rodríguez-Pintó I, Cervera R, Gregory S, de Meis E, Rodrigues CE, Aikawa NE, de Carvalho JF, Springer J, Niedzwiecki M, Espinosa G; Catastrophic Registry Project Group (European Forum on Antiphospholipid Antibodies).

Autoimmun Rev. 2014 Feb;13(2):157-62. doi: 10.1016/j.autrev.2013.10.004. Epub 2013 Oct 19.

PMID:
24145009
29.

Catastrophic antiphospholipid syndrome - 20 years later.

Rodríguez-Pintó I, Espinosa G, Cervera R.

Curr Rheumatol Rev. 2013;9(2):73-80.

PMID:
25409664
30.

Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab.

Berman H, Rodríguez-Pintó I, Cervera R, Morel N, Costedoat-Chalumeau N, Erkan D, Shoenfeld Y, Espinosa G; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies).

Autoimmun Rev. 2013 Sep;12(11):1085-90. doi: 10.1016/j.autrev.2013.05.004. Epub 2013 Jun 15.

PMID:
23777822
31.

Relapsing catastrophic antiphospholipid syndrome potential role of microangiopathic hemolytic anemia in disease relapses.

Espinosa G, Rodríguez-Pintó I, Gomez-Puerta JA, Pons-Estel G, Cervera R; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies).

Semin Arthritis Rheum. 2013 Feb;42(4):417-23. doi: 10.1016/j.semarthrit.2012.05.005. Epub 2012 Jul 10.

PMID:
22784445
32.

[Native valve endocarditis due to Staphylococcus aureus].

Rodríguez-Pintó I, Pons Masanés S, Igual Barceló A.

Med Clin (Barc). 2013 Jan 5;140(1):48. doi: 10.1016/j.medcli.2012.04.011. Epub 2012 Jun 27. Spanish. No abstract available.

PMID:
22743276
33.

Regulatory T cells in the pathogenesis and healing of chronic human dermal leishmaniasis caused by Leishmania (Viannia) species.

Rodriguez-Pinto D, Navas A, Blanco VM, Ramírez L, Garcerant D, Cruz A, Craft N, Saravia NG.

PLoS Negl Trop Dis. 2012;6(4):e1627. doi: 10.1371/journal.pntd.0001627. Epub 2012 Apr 24.

34.

IL-10-conditioned dendritic cells prevent autoimmune diabetes in NOD and humanized HLA-DQ8/RIP-B7.1 mice.

Tai N, Yasuda H, Xiang Y, Zhang L, Rodriguez-Pinto D, Yokono K, Sherwin R, Wong FS, Nagata M, Wen L.

Clin Immunol. 2011 Jun;139(3):336-49. doi: 10.1016/j.clim.2011.03.003. Epub 2011 Mar 9.

PMID:
21458378
35.

Disruption of protein kinase A localization using a trans-activator of transcription (TAT)-conjugated A-kinase-anchoring peptide reduces cardiac function.

Patel HH, Hamuro LL, Chun BJ, Kawaraguchi Y, Quick A, Rebolledo B, Pennypacker J, Thurston J, Rodriguez-Pinto N, Self C, Olson G, Insel PA, Giles WR, Taylor SS, Roth DM.

J Biol Chem. 2010 Sep 3;285(36):27632-40. doi: 10.1074/jbc.M110.146589. Epub 2010 Jun 26.

36.

Inflammatory regulation by TLR3 in acute hepatitis.

Xiao X, Zhao P, Rodriguez-Pinto D, Qi D, Henegariu O, Alexopoulou L, Flavell RA, Wong FS, Wen L.

J Immunol. 2009 Sep 15;183(6):3712-9. doi: 10.4049/jimmunol.0901221. Epub 2009 Aug 26.

37.

Identification of novel tumor antigens with patient-derived immune-selected antibodies.

Rodriguez-Pinto D, Sparkowski J, Keough MP, Phoenix KN, Vumbaca F, Han DK, Gundelfinger ED, Beesley P, Claffey KP.

Cancer Immunol Immunother. 2009 Feb;58(2):221-34. doi: 10.1007/s00262-008-0543-0. Epub 2008 Jun 21.

38.

Hormonal regulation of B-cell function and systemic lupus erythematosus.

Cohen-Solal JF, Jeganathan V, Hill L, Kawabata D, Rodriguez-Pinto D, Grimaldi C, Diamond B.

Lupus. 2008 Jun;17(6):528-32. doi: 10.1177/0961203308089402. Review.

PMID:
18539705
39.

CD13 is a novel mediator of monocytic/endothelial cell adhesion.

Mina-Osorio P, Winnicka B, O'Conor C, Grant CL, Vogel LK, Rodriguez-Pinto D, Holmes KV, Ortega E, Shapiro LH.

J Leukoc Biol. 2008 Aug;84(2):448-59. doi: 10.1189/jlb.1107802. Epub 2008 May 21.

40.

Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice.

Hu CY, Rodriguez-Pinto D, Du W, Ahuja A, Henegariu O, Wong FS, Shlomchik MJ, Wen L.

J Clin Invest. 2007 Dec;117(12):3857-67.

41.

Double-stranded RNA-binding protein regulates vascular endothelial growth factor mRNA stability, translation, and breast cancer angiogenesis.

Vumbaca F, Phoenix KN, Rodriguez-Pinto D, Han DK, Claffey KP.

Mol Cell Biol. 2008 Jan;28(2):772-83. Epub 2007 Nov 26.

42.

Patterns of Guillain-Barre syndrome in children: results from a Mexican population.

Nachamkin I, Arzarte Barbosa P, Ung H, Lobato C, Gonzalez Rivera A, Rodriguez P, Garcia Briseno A, Cordero LM, Garcia Perea L, Perez JC, Ribera M, Aldama PC, Guitérrez GD, Sarnat LF, García MR, Veitch J, Fitzgerald C, Cornblath DR, Rodriguez Pinto M, Griffin JW, Willison HJ, Asbury AK, McKhann GM.

Neurology. 2007 Oct 23;69(17):1665-71. Epub 2007 Sep 26. Erratum in: Neurology. 2009 Mar 24;72(12):1110. Barbosa, P Arzate [corrected to Arzarte Barbosa, P]; Ung, H [corrected to Ung, Huong]; Rivera, A Gonzalez [corrected to Gonzalez Rivera, A]; Briseno, A Garcia [corrected to Garcia Briseno, A]; Perea, L Garcia [corrected to Garcia Perea, L]; Aldama, P Chico.

PMID:
17898327
43.

B cells as antigen presenting cells.

Rodríguez-Pinto D.

Cell Immunol. 2005 Dec;238(2):67-75. Epub 2006 Mar 30. Review.

PMID:
16574086
45.

Hepatitis G virus infection markers (RNA and anti-E2 antibodies) in a multicenter cohort of hemophiliacs.

Tàssies D, Magallón M, Quintana M, Fernández-Urgellés RP, Rodriguez-Pinto C, Tusell J, Altisent C, Reverter JC, Mazzara R, Ordinas A, Monteagudo J.

Haematologica. 1999 Oct;84(10):930-6.

46.

[Thrombophilia in patients with venous thromboembolism].

Rodríguez Pinto MC, Fernández Urgellés M, Soto Ortega I, García Gala JM, Rosón Porto C, Corte Buelga JR.

Sangre (Barc). 1996 Feb;41(1):37-42. Spanish.

PMID:
8779033
47.

Prospective study of antigenemia, plasma viremia and lymphocytic viremia in HIV-infected hemophiliacs.

Melón Garcia S, de Oña Navarro M, Rodriguez Pinto C, Fernández Urgellés M, Martinez Gutierrez A, de la Iglesia P, Mendez García FJ.

Eur J Clin Microbiol Infect Dis. 1995 May;14(5):400-5.

PMID:
7556228
48.

Activated protein C: new facts.

Soto Ortega I, Garcia Gala JM, Rodriguez Pinto C.

Blood Coagul Fibrinolysis. 1995 Apr;6(2):144. No abstract available.

PMID:
7605883
49.

[Antiphospholipid antibodies in human immunodeficiency virus infection].

Llorente MR, Carton JA, Cárcaba V, Rodríguez-Pinto C, Maradona JA, Asensi V, Fernández-Urgellés M.

Med Clin (Barc). 1994 Jun 4;103(1):10-3. Spanish.

PMID:
8051959
50.

Fibrinogen Oviedo I. A new Spanish dysfibrinogenaemia.

Fernández FJ, Rodríguez Pinto C, Páramo J, Cuesta B, Collado M, Rocha E.

Blood Coagul Fibrinolysis. 1990 Oct;1(4-5):571-5.

PMID:
2133236

Supplemental Content

Loading ...
Support Center